QGEN Qiagen NV

$46.31

*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.

Reporting for fiscal period ending —
Expected on —
Report Time: Unknown Release Time
The Whisper Number
—
Consensus Estimate: —
Revenue Estimate: —

Latest Earnings Insight

Updated On 10/2/2025

About Qiagen NV

QIAGEN NV provides sample-to-knowledge solutions that transform biological materials into molecular knowledge globally. The company is headquartered in Venlo, the Netherlands.

Website: https://www.qiagen.com

Sector
LIFE SCIENCES
Industry
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Exchange
NYSE
Country
USA
Currency
USD
Fiscal Year End
December
CIK
1015820
Address
HULSTERWEG 82, PL VENLO, NL
Valuation
Market Cap
$8.80B
P/E Ratio
107.13
PEG Ratio
0.94
Price to Book
2.47
Performance
EPS
$0.38
Dividend Yield
2.94%
Profit Margin
4.23%
ROE
2.27%
Technicals
50D MA
$39.80
200D MA
$43.06
52W High
$47.96
52W Low
$37.63
Fundamentals
Shares Outstanding
216M
Target Price
$49.23
Beta
0.62

QGEN EPS Estimates vs Actual

● Estimated
● Actual

QGEN News & Sentiment

Oct 01, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Quest Diagnostics Joins Forces With Epic to Improve Laboratory Testing
DGX teams up with Epic on Project Nova to streamline lab testing, boost efficiency, and enhance patient and provider experiences.
Sep 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
PacBio Enters Carrier Screening Market With PureTarget Expansion
PACB expands its PureTarget portfolio, streamlining carrier screening with HiFi sequencing to meet rising global demand.
Sep 30, 2025 • Zacks Commentary SOMEWHAT-BULLISH
QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test
QDEL boosts its respiratory testing lineup with the FDA-cleared QUICKVUE Influenza + SARS Test for professional use.
Sep 30, 2025 • Zacks Commentary NEUTRAL
DGX's Haystack Oncology Teams Up With Rutgers Cancer Institute
Quest Diagnostics' Haystack Oncology joins Rutgers Cancer Institute to study how its ctDNA MRD test can guide therapy for stage II/III lung cancer.
Sep 23, 2025 • Zacks Commentary SOMEWHAT-BULLISH
Tempus AI Enhances Cancer Research Tools With FDA-Cleared xR IVD
TEM secures FDA clearance for its xR IVD device, advancing RNA-based cancer research and precision medicine tools.
Sep 19, 2025 • Zacks Commentary SOMEWHAT-BULLISH
INCY Obtains FDA Approval for Label Expansion of Ruxolitinib Cream
Incyte secures FDA nod for Opzeluras pediatric use in atopic dermatitis, marking its third U.S. approval and boosting sales momentum.
Sentiment Snapshot

Average Sentiment Score:

0.292
50 articles with scored sentiment

Overall Sentiment:

Bullish

QGEN Reported Earnings

Apr 30, 2025
Mar 31, 2025 (Post market)
0.0 Surprise
  • Reported EPS: $0.00
  • Estimate: $0.00
  • Whisper: —
  • Surprise %: 0.0%
Feb 06, 2025
Dec 31, 2024 (Pre market)
-0.01 Surprise
  • Reported EPS: $0.61
  • Estimate: $0.62
  • Whisper: —
  • Surprise %: -1.3%
Nov 06, 2024
Sep 30, 2024 (Post market)
0.03 Surprise
  • Reported EPS: $0.57
  • Estimate: $0.54
  • Whisper: —
  • Surprise %: 5.6%
Jul 31, 2024
Jun 30, 2024 (Post market)
0.04 Surprise
  • Reported EPS: $0.55
  • Estimate: $0.51
  • Whisper: —
  • Surprise %: 7.8%
Apr 29, 2024
Mar 31, 2024 (Post market)
0.02 Surprise
  • Reported EPS: $0.46
  • Estimate: $0.44
  • Whisper: —
  • Surprise %: 4.5%
Feb 06, 2024
Dec 31, 2023 (Post market)
0.0 Surprise
  • Reported EPS: $0.55
  • Estimate: $0.55
  • Whisper: —
  • Surprise %: 0.0%
Oct 30, 2023
Sep 30, 2023 (Post market)
0.02 Surprise
  • Reported EPS: $0.50
  • Estimate: $0.48
  • Whisper: —
  • Surprise %: 4.2%
Aug 08, 2023
Jun 30, 2023 (Post market)
0.01 Surprise
  • Reported EPS: $0.51
  • Estimate: $0.50
  • Whisper: —
  • Surprise %: 2.0%
May 03, 2023
Mar 31, 2023 (Post market)
0.04 Surprise
  • Reported EPS: $0.51
  • Estimate: $0.47
  • Whisper: —
  • Surprise %: 8.5%

Financials